tradingkey.logo

HUTCHMED (China) Ltd

HCM
15.180USD
+0.610+4.19%
Handelsschluss 02/06, 16:00ETKurse um 15 Minuten verzögert
13.24BMarktkapitalisierung
28.07KGV TTM

HUTCHMED (China) Ltd

15.180
+0.610+4.19%

mehr Informationen über HUTCHMED (China) Ltd Unternehmen

HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.

HUTCHMED (China) Ltd Informationen

BörsenkürzelHCM
Name des UnternehmensHUTCHMED (China) Ltd
IPO-datumMay 19, 2006
CEOCheng (Chig Fung)
Anzahl der mitarbeiter1811
WertpapierartDepository Receipt
GeschäftsjahresendeMay 19
Addresse48th Floor, Cheung Kong Center, 2 Queen's Road Central
Stadt
BörseNASDAQ OMX - NASDAQ BASIC
LandHong Kong
Postleitzahl- -
Telefon85221281188
Websitehttps://www.hutch-med.com/
BörsenkürzelHCM
IPO-datumMay 19, 2006
CEOCheng (Chig Fung)

Führungskräfte von HUTCHMED (China) Ltd

Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Ling Yang
Ms. Ling Yang
Non-Executive Director
Non-Executive Director
--
--
Mr. David Ng
Mr. David Ng
Vice President
Vice President
--
--
Dr. Renu Bhatia
Dr. Renu Bhatia
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. Chaohong (Mary) Hu
Dr. Chaohong (Mary) Hu
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Tak Wai (Alvin) Wong
Mr. Tak Wai (Alvin) Wong
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Prof. Shao Weng (Daniel) Tan
Prof. Shao Weng (Daniel) Tan
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Ms. Edith Shih
Ms. Edith Shih
Non-Executive Director, Company Secretary
Non-Executive Director, Company Secretary
--
--
Mr. Chig Fung (Johnny) Cheng
Mr. Chig Fung (Johnny) Cheng
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Dr. Dan Eldar, Ph.D.
Dr. Dan Eldar, Ph.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Dr. Weiguo Su, Ph.D.
Dr. Weiguo Su, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Ling Yang
Ms. Ling Yang
Non-Executive Director
Non-Executive Director
--
--
Mr. David Ng
Mr. David Ng
Vice President
Vice President
--
--
Dr. Renu Bhatia
Dr. Renu Bhatia
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. Chaohong (Mary) Hu
Dr. Chaohong (Mary) Hu
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Tak Wai (Alvin) Wong
Mr. Tak Wai (Alvin) Wong
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Prof. Shao Weng (Daniel) Tan
Prof. Shao Weng (Daniel) Tan
Independent Non-Executive Director
Independent Non-Executive Director
--
--

Umsatzaufteilung

Währung: USDAktualisiert: Tue, Jan 6
Währung: USDAktualisiert: Tue, Jan 6
FY2024
FY2023
FY2022
FY2021
FY2020
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach RegionUSD
Name
Umsatz
Anteil
PRC
630.20M
0.00%
Unallocated
0.00
0.00%
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: Sat, Feb 7
Aktualisiert: Sat, Feb 7
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Schroder Investment Management (Singapore) Ltd.
0.97%
Allianz Global Investors Asia Pacific Limited
0.49%
Schroder Investment Management (Hong Kong) Ltd.
0.45%
Jane Street Capital, L.L.C.
0.20%
State Street Investment Management (US)
0.18%
Andere
97.71%
Aktionäre
Aktionäre
Anteil
Schroder Investment Management (Singapore) Ltd.
0.97%
Allianz Global Investors Asia Pacific Limited
0.49%
Schroder Investment Management (Hong Kong) Ltd.
0.45%
Jane Street Capital, L.L.C.
0.20%
State Street Investment Management (US)
0.18%
Andere
97.71%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
2.30%
Investment Advisor
0.65%
Research Firm
0.22%
Hedge Fund
0.13%
Bank and Trust
0.03%
Sovereign Wealth Fund
0.01%
Andere
96.66%

Institutionelle Beteiligung

Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
143
5.89M
3.38%
-5.77M
2025Q3
144
6.22M
3.56%
-5.80M
2025Q2
160
6.97M
3.99%
-6.31M
2025Q1
166
6.98M
4.00%
-6.73M
2024Q4
187
7.28M
4.18%
-8.01M
2024Q3
259
7.73M
4.44%
-16.35M
2024Q2
280
9.29M
5.33%
-17.79M
2024Q1
306
15.01M
8.61%
-19.39M
2023Q4
327
16.63M
9.55%
-27.28M
2023Q3
339
25.00M
14.36%
-20.50M
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Schroder Investment Management (Singapore) Ltd.
1.69M
0.97%
-84.85K
-4.78%
Sep 30, 2025
Allianz Global Investors Asia Pacific Limited
863.00K
0.49%
-15.73K
-1.79%
Sep 30, 2025
Schroder Investment Management (Hong Kong) Ltd.
778.26K
0.45%
-27.37K
-3.40%
Sep 30, 2025
Jane Street Capital, L.L.C.
340.34K
0.2%
+164.38K
+93.42%
Sep 30, 2025
State Street Investment Management (US)
317.50K
0.18%
-11.29K
-3.43%
Sep 30, 2025
AIA Group Ltd
315.44K
0.18%
--
--
Sep 30, 2025
Amundi Asset Management, SAS
223.33K
0.13%
+65.90K
+41.86%
Sep 30, 2025
M&G Investment Management Ltd.
204.43K
0.12%
-55.19K
-21.26%
Sep 30, 2025
Renaissance Technologies LLC
131.00K
0.08%
+2.00K
+1.55%
Sep 30, 2025
Saint Olive Gestion
100.00K
0.06%
--
--
Sep 30, 2025
Mehr Anzeigen

Verbundene ETFs

Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Tema Oncology ETF
0.78%
National Security Emerging Markets Index ETF
0.35%
Invesco Nasdaq Biotechnology ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.05%
DFA Dimensional Emerging Markets Core Equity 2 ETF
0%
DFA Dimensional Em Mkts Sustainability Core 1 ETF
0%
ActivePassive International Equity ETF
0%
SPDR Portfolio Developed World ex-US ETF
0%
Tema Oncology ETF
Anteil0.78%
National Security Emerging Markets Index ETF
Anteil0.35%
Invesco Nasdaq Biotechnology ETF
Anteil0.05%
ProShares Ultra Nasdaq Biotechnology
Anteil0.05%
DFA Dimensional Emerging Markets Core Equity 2 ETF
Anteil0%
DFA Dimensional Em Mkts Sustainability Core 1 ETF
Anteil0%
ActivePassive International Equity ETF
Anteil0%
SPDR Portfolio Developed World ex-US ETF
Anteil0%

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
KeyAI